These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2277127)

  • 21. [Influence of retinoids on the bioavailability of methoxy-8-psoralen].
    Beani JC; Bonnot D; Berthod F; Boitard M; Reymond JL; Beriel H; Amblard P
    Ann Dermatol Venereol; 1991; 118(4):273-5. PubMed ID: 2069337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement.
    Mahrle G; Schulze HJ; Färber L; Weidinger G; Steigleder GK
    J Am Acad Dermatol; 1995 Jan; 32(1):78-88. PubMed ID: 7822521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pharmacokinetics of etretinate, acitretin and 13-cis-acitretin: new results and advantages of blood level oriented clinical use].
    Gollnick H; Rinck G; Bitterling T; Orfanos CE
    Z Hautkr; 1990 Jan; 65(1):40-50. PubMed ID: 2139274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of biological variables upon pharmacokinetic parameters of intramuscular methotrexate in rheumatoid arthritis.
    Debord J; Carpentier N; Sabot C; Bertin P; Marquet P; Treves R; Merle L; Lachâtre G
    Int J Clin Pharmacol Ther; 1998 Apr; 36(4):227-30. PubMed ID: 9587050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methotrexate pharmacokinetics in psoriatic patients developing hepatic fibrosis.
    Jones SK; Aherne GW; Campbell MJ; White JE
    Arch Dermatol; 1986 Jun; 122(6):666-9. PubMed ID: 3717976
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug eruption caused by nitrazepam in a patient with severe pustular psoriasis successfully treated with methotrexate and etretinate.
    Shoji A; Kitajima J; Hamada T
    J Dermatol; 1987 Jun; 14(3):274-8. PubMed ID: 2959694
    [No Abstract]   [Full Text] [Related]  

  • 27. Etretinate pharmacokinetics in chronic renal failure. A preliminary study in psoriasis patients.
    Vahlquist A
    Dermatologica; 1987; 175(5):224-8. PubMed ID: 2960573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Etretinate. Persistent serum levels after long-term therapy.
    DiGiovanna JJ; Zech LA; Ruddel ME; Gantt G; Peck GL
    Arch Dermatol; 1989 Feb; 125(2):246-51. PubMed ID: 2913962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.
    Hroch M; Chladek J; Simkova M; Vaneckova J; Grim J; Martinkova J
    J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):19-24. PubMed ID: 18031504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [How to choose a basic drug for psoriatic arthritis?].
    Koó E; Seszták M; Gyulai F; Farkas V
    Orv Hetil; 1991 Dec; 132(49):2709-12, 2715-6. PubMed ID: 1684842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis.
    Bannwarth B; Péhourcq F; Schaeverbeke T; Dehais J
    Clin Pharmacokinet; 1996 Mar; 30(3):194-210. PubMed ID: 8882301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Etretinate administration reduces serum propeptide of type I procollagen level in patients with psoriasis.
    Osada K; Seishima M; Mori S; Seishima M; Takemura M; Noma A
    Br J Dermatol; 1994 Nov; 131(5):655-9. PubMed ID: 7999596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decreased urinary polyamines in patients with psoriasis treated with etretinate.
    Grekin RC; Ellis CN; Goldstein NG; Swanson NA; Anderson TF; Duell EA; Voorhees JJ
    J Invest Dermatol; 1983 Mar; 80(3):181-4. PubMed ID: 6827127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Erythrocyte membrane phosphorylation in untreated and in etretinate-treated psoriatic patients.
    Kumar R; Weiss VC; West DP; Chiero LA
    Br J Dermatol; 1983 Sep; 109(3):277-86. PubMed ID: 6615715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Etretinate therapy for psoriasis. Reduction of antibody-dependent cell-mediated cytotoxicity of polymorphonuclear leukocytes.
    Ellis CN; Kang S; Grekin RC; LoBuglio AF; Voorhees JJ
    Arch Dermatol; 1985 Jul; 121(7):877-80. PubMed ID: 4015133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acitretin versus etretinate in severe psoriasis. A double-blind randomized Nordic multicenter study in 168 patients.
    Bjerke JR; Geiger JM
    Acta Derm Venereol Suppl (Stockh); 1989; 146():206-7. PubMed ID: 2532847
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of low doses of methotrexate in patients with psoriasis over the early period of treatment.
    Chládek J; Martínková J; Simková M; Vanecková J; Koudelková V; Nozicková M
    Eur J Clin Pharmacol; 1998 Feb; 53(6):437-44. PubMed ID: 9551702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trimethylpsoralen bath plus ultraviolet A combined with oral retinoid (etretinate) in the treatment of severe psoriasis.
    Väätäinen N; Hollmen A; Fräki JE
    J Am Acad Dermatol; 1985 Jan; 12(1 Pt 1):52-5. PubMed ID: 3980803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The pharmacokinetics of acitretin and its 13-cis-metabolite in psoriatic patients.
    Larsen FG; Jakobsen P; Eriksen H; Grønhøj J; Kragballe K; Nielsen-Kudsk F
    J Clin Pharmacol; 1991 May; 31(5):477-83. PubMed ID: 1828811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical trial of the efficacy and safety of oral etretinate with calcipotriol cream compared with etretinate alone in moderate-severe psoriasis.
    Giannetti A; Coppini M; Bertazzoni MG; Califano A; Altieri E; Pazzaglia A; Lega M; Lombardo M; Pelfini C; Veller Fornasa C; Rabbiosi G; Cespa M
    J Eur Acad Dermatol Venereol; 1999 Sep; 13(2):91-5. PubMed ID: 10568486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.